Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Métodos Terapêuticos e Terapias MTCI
Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Biochem Biophys Res Commun ; 500(2): 435-442, 2018 06 02.
Artigo em Inglês | MEDLINE | ID: mdl-29660334

RESUMO

BACKGROUND: Effects of lutein (L) and fatty acids [linoleic acid (LA), eicosapentaenoic acid (EPA)+docosahexaenoic acid (DHA) and oleic acid (OA)] on oxidative stress and inflammation in cataract were assessed. METHODS: Cataract was induced in male Wistar rat pups (11 days old) by giving a single dose of sodium selenite (25 µM/kg body weight) by IP. Lutein (1.3 µmol/kg body weight) was given one day before and five days after selenite injection as a micelle with 7.5 mM LA, or 7.5 mM EPA + DHA or 7.5 mM OA. Serum and lens oxidative stress and inflammatory parameters having a bearing cataract were assessed. RESULTS: Serum and lens nitric oxide, MDA and protein carbonyls were significantly (p < 0.05) increased in cataract compared to control and experimental groups. Catalase, SOD, glutathione peroxidase and glutathione transferase activity and glutathione level in serum and lens of cataract group were significantly (p < 0.05) decreased. Serum eicosanoids (PGE2, LTB4, and LTC4) and cytokines (CRP, TNF-α, IL1-ß, and MCP-1) were significantly (p < 0.05) increased in cataract. The activity of cPLA2 and Cox-2 in cataract lens was higher (p < 0.05) compared to other groups. EP-1, NOS-2 and NF-kB expression were higher (p < 0.05) in cataract. The ratio of water insoluble to water soluble protein was increased in cataract lens. Group administered with L + EPA + DHA exhibited highest cataract prevention compared to L + LA and L + OA. Pups given lutein with EPA + DHA had the highest amount of lutein in the lens. CONCLUSIONS: The anti-cataract activity of lutein was influenced by fatty acids and found to be highest with EPA + DHA compared to LA or OA.


Assuntos
Catarata/tratamento farmacológico , Catarata/prevenção & controle , Ácidos Graxos/uso terapêutico , Inflamação/tratamento farmacológico , Luteína/uso terapêutico , Estresse Oxidativo , Animais , Antioxidantes/metabolismo , Biomarcadores/sangue , Catarata/sangue , Ciclo-Oxigenase 2/metabolismo , Citocinas/sangue , Eicosanoides/sangue , Proteínas do Olho/metabolismo , Ácidos Graxos/farmacologia , Glutationa/sangue , Glutationa/metabolismo , Inflamação/patologia , Cristalino/metabolismo , Cristalino/patologia , Luteína/farmacologia , Masculino , Modelos Biológicos , NF-kappa B/metabolismo , Óxido Nítrico Sintase Tipo II/metabolismo , Estresse Oxidativo/efeitos dos fármacos , Fosfolipases A2 Citosólicas/metabolismo , Ratos , Receptores de Prostaglandina E Subtipo EP1/metabolismo , Solubilidade , Água
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA